Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCash Due from BankCommon EquityFed Funds SoldLiabilities and Shareholders EquityLoans - GrossLoans - Loss AllowanceLoans - NetNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Retained EarningsSecuritiesSecurities - Mortgage Backed SecuritiesSecurities - TradableShareholder's EquityShort-term InvestmentsTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MetroCity Bankshares (MCBS) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for MetroCity Bankshares (MCBS) over the last 8 years, with Q3 2025 value amounting to $227.2 million.

  • MetroCity Bankshares' Cash & Equivalents fell 2199.62% to $227.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.2 million, marking a year-over-year decrease of 2199.62%. This contributed to the annual value of $249.9 million for FY2024, which is 7255.96% up from last year.
  • MetroCity Bankshares' Cash & Equivalents amounted to $227.2 million in Q3 2025, which was down 2199.62% from $286.0 million recorded in Q2 2025.
  • Over the past 5 years, MetroCity Bankshares' Cash & Equivalents peaked at $441.3 million during Q4 2021, and registered a low of $144.8 million during Q4 2023.
  • In the last 5 years, MetroCity Bankshares' Cash & Equivalents had a median value of $258.8 million in 2024 and averaged $264.7 million.
  • In the last 5 years, MetroCity Bankshares' Cash & Equivalents soared by 19288.4% in 2021 and then tumbled by 5933.19% in 2022.
  • Quarter analysis of 5 years shows MetroCity Bankshares' Cash & Equivalents stood at $441.3 million in 2021, then crashed by 59.33% to $179.5 million in 2022, then decreased by 19.32% to $144.8 million in 2023, then surged by 72.56% to $249.9 million in 2024, then dropped by 9.09% to $227.2 million in 2025.
  • Its Cash & Equivalents stands at $227.2 million for Q3 2025, versus $286.0 million for Q2 2025 and $285.1 million for Q1 2025.